Hemispherian’s targeted therapeutics act on an entirely new mechanism of action. These drugs work by restoring a cancer cell’s normal epigenetic complement. The drug-induced restoration of this modified DNA base triggers the DNA damage response and results in cancer cytotoxicity. Treatment with these compounds is highly targeted towards cancers and is well tolerated in normal tissues.

Targeted cancer therapeutics redefined

The modified DNA base, 5-hydroxymethylcytosine, is universally depleted in cancers. The TET2 enzyme synthesizes genomic 5-hydroxymethylcytosine. Rapid reestablishment of 5-hydroxymethylcytosine invokes the DNA damage response, leading to cancer cell death. Hemispherian’s proprietary GLIX molecules act on TET2 to increase genomic 5-hydroxymethylcytosine levels. The GLIX molecules are cancer cytotoxic in vitro and in vivo animal models.

More information

For more information about Hemispherian visit www.hemispherian.com.